Please assess the completion status of the following clinical trial:

Trial Title: Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of onychomycosis of at least one great toenail~* Percent Nail Involvement Score of the more severely affected great toenail (the Target Toenail) must be between 2 and 3 (25-75% of the nail unit).~* Length of Unaffected Part of the Target Toenail ≥2mm~* Direct microscopic examination with KOH that is positive for the hyphae associated with dermatophytes on the target toenail~* Subjects must have signed informed consent~* If the subject is woman of childbearing potential, she must have a negative urine pregnancy test and agree to use an effective form of birth control until the first menses after 60 days following the last dose of study medication.~Exclusion Criteria:~* Onychomycosis caused by Candida spp. without the presence of a dermatophyte~* Participation in a clinical trial for the systemic treatment of onychomycosis of the toenail within 24 weeks prior to Visit 1~* Use of systemic antifungals within 12 weeks prior to Visit 1~* Use of topical antifungal nail lacquer within 30 days prior to Visit 1~* Use of any other topical onychomycosis treatment on any toenail within 7 days prior to Visit 1~* Evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF~* Known liver disease or a history of liver toxicity with other drugs~* Use of systemic immunosuppressants

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Itraconazole tablets (Type: EXPERIMENTAL): Itraconazole 200 mg tablets
- Itraconazole capsules (Type: ACTIVE_COMPARATOR): Two Itraconazole 100 mg capsules were taken daily.
- Placebo tablets (Type: PLACEBO_COMPARATOR): The itraconazole 200-mg tablets and placebo tablets exactly matched one another and were white to slightly grey in color, were oblong and biconvex in shape, and were melt-extrusion, film-coated.

Based on this trial design, predict the completion outcome and termination type (if applicable).